MassChallenge Startups Create Impact


Startups Accelerated


Funding Raised


Revenue Generated


Jobs Created

Our startups

Be inspired. Search our startups.

MyoGene Bio

MyoGene Bio is developing therapies for muscle diseases starting with a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy, a devastating fatal muscle wasting disease. We have demonstrated proof-of-efficacy that MyoDys45-55 can restore the protein otherwise lacking in Duchenne, expected to significantly improve the disease course and lifespan for about half of all Duchenne patients. MyoGene Bio is currently working to complete preclinical development to translate this therapy.
MyoGene Bio is developing cutting edge therapies for muscle diseases, starting with a gene editing therapy for Duchenne muscular dystrophy.

Connect with MyoGene Bio

MyoGene Bio


2021 Silver RI-98

Sub industry

Therapeutics (Pharma / Biotech)


Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.